Literature DB >> 11774033

Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP.

M S Maliner-Stratton1, R D Klein, T S Udayakumar, R B Nagle, G T Bowden.   

Abstract

Previously, our laboratory showed that interleukin-1beta (IL-1beta) secreted by lipopolysaccharide-activated monocytes induces promatrilysin expression in the prostate carcinoma cell line, LNCaP. We now demonstrate that IL-1beta-induced promatrilysin expression is mediated by an indirect mechanism that requires nuclear factor Kappa B (NFkappaB)-dependent synthesis of IL-6. Inhibition of protein synthesis with cycloheximide blocked IL-1beta-mediated induction of matrilysin mRNA suggesting that synthesis of one or more additional factors is required for IL-1beta-induced promatrilysin protein expression. Blockage of NFkappaB transactivation activity abrogated IL-1beta-induced promatrilysin expression to baseline levels suggesting that NFkappaB transactivation activity is necessary. Inhibition of IL-6 activity attenuated IL-1beta-induced promatrilysin, but not NFkappaB transactivation activity indicating that IL-6 acts downstream of NFkappaB in potentiation of IL-1beta-mediated promatrilysin expression. Inhibition of protein synthesis with cycloheximide did not alter IL-6-induced induction of matrilysin mRNA indicating that, contrary to the mechanism by which IL-1beta regulates promatrilysin expression, IL-6-mediated matrilysin mRNA expression does not require new protein synthesis. Transient transfection with dominant negative STAT3 inhibited IL-1beta- and IL-6-induced promatrilysin. These data provide evidence that NFkappaB-mediated IL-6 synthesis is required for IL-1beta-induced promatrilysin expression, and IL-6 signaling through STAT3 plays a role in IL-1beta-induced promatrilysin expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11774033      PMCID: PMC1506568          DOI: 10.1038/sj.neo.7900178

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  58 in total

1.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma.

Authors:  H L Adler; M A McCurdy; M W Kattan; T L Timme; P T Scardino; T C Thompson
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

2.  EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP.

Authors:  P Sundareshan; R B Nagle; G T Bowden
Journal:  Prostate       Date:  1999-08-01       Impact factor: 4.104

3.  Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements.

Authors:  A R Farina; A Tacconelli; A Vacca; M Maroder; A Gulino; A R Mackay
Journal:  Cell Growth Differ       Date:  1999-05

4.  Interleukin-6 increases rat metalloproteinase-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts.

Authors:  J A Solís-Herruzo; R A Rippe; L W Schrum; P de La Torre; I García; J J Jeffrey; T Muñoz-Yagüe; D A Brenner
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

5.  Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas.

Authors:  A E Kossakowska; D R Edwards; C Prusinkiewicz; M C Zhang; D Guo; S J Urbanski; T Grogan; L A Marquez; A Janowska-Wieczorek
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group.

Authors:  J Irani; J M Goujon; E Ragni; L Peyrat; J Hubert; F Saint; N Mottet
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

7.  Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.

Authors:  D E Drachenberg; A A Elgamal; R Rowbotham; M Peterson; G P Murphy
Journal:  Prostate       Date:  1999-10-01       Impact factor: 4.104

8.  Analysis of interleukin (IL)-1 beta and transforming growth factor (TGF)-beta-induced signal transduction pathways in IL-2 and TGF-beta secretion and proliferation in the thymoma cell line EL4.NOB-1.

Authors:  A Siese; P P Jaros; A Willig
Journal:  Scand J Immunol       Date:  1999-02       Impact factor: 3.487

9.  Characterization of the role of IL-6 in the progression of prostate cancer.

Authors:  T D Chung; J J Yu; M T Spiotto; M Bartkowski; J W Simons
Journal:  Prostate       Date:  1999-02-15       Impact factor: 4.104

10.  Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.

Authors:  M Kawada; M Ishizuka; T Takeuchi
Journal:  Jpn J Cancer Res       Date:  1999-05
View more
  5 in total

1.  Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1β.

Authors:  Julia A Staverosky; Xin-Hua Zhu; Susan Ha; Susan K Logan
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

2.  Fibroblast growth factor-1 induced promatrilysin expression through the activation of extracellular-regulated kinases and STAT3.

Authors:  Thirupandiyur S Udayakumar; Mimi Suzanne Stratton; Raymond B Nagle; George Timothy Bowden
Journal:  Neoplasia       Date:  2002 Jan-Feb       Impact factor: 5.715

3.  Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.

Authors:  Howard C Crawford; Charles R Scoggins; M Kay Washington; Lynn M Matrisian; Steven D Leach
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells.

Authors:  J Megías; J Busserolles; M J Alcaraz
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

5.  "Soldier's Heart": A Genetic Basis for Elevated Cardiovascular Disease Risk Associated with Post-traumatic Stress Disorder.

Authors:  Harvey B Pollard; Chittari Shivakumar; Joshua Starr; Ofer Eidelman; David M Jacobowitz; Clifton L Dalgard; Meera Srivastava; Matthew D Wilkerson; Murray B Stein; Robert J Ursano
Journal:  Front Mol Neurosci       Date:  2016-09-23       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.